NEW ZEALAND GAZETTE, No. 96

7 JULY 2011

• Heparins; for internal use; except when present as an excipient
• Human papillomavirus vaccine
• Ibogaine
• Japanese encephalitis vaccine
• Lansoprazole; except when specified elsewhere in this notice
• Loperamide; except when specified elsewhere in this notice
• Nebivolol
• Noribogaine
• Omeprazole; except when specified elsewhere in this notice
• Pazopanib
• Phosphodiesterase type 5 inhibitors; except when present as an unmodified, naturally occurring substance; except when specified elsewhere in this notice
• Rizatriptan; except when specified elsewhere in this notice
• Roflumilast
• Saxagliptin
• Staphylococcus aureus vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds
• Stramonium; except for oral use when specified elsewhere in this notice; except datura stramonium or datura tatula for smoking or burning
• Streptococcus beta-haemolyticus vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds
• Succimer
• Tapentadol
• Ustekinumab
• Vaccines; except when specified elsewhere in this notice
• Vaccinia virus vaccine
• Vernakalant
• Vinflunine
• Zolmitriptan; except when specified elsewhere in this notice

Schedule 2

Restricted Medicines

• Chloramphenicol; for ophthalmic use; except when sold in practice by a registered optometrist
• Codeine; in medicines for oral use, containing not more than 15 milligrams of codeine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of codeine, when combined with 1 or more active ingredients, in such a way that the substance cannot be recovered by readily applicable means or in a yield which would constitute a risk to health, for use as an analgesic and when sold in a pack of not more than 5 days' supply, approved by the Minister or the Director-General for distribution as a restricted medicine
• Famciclovir; in tablets containing 500 milligrams or less when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine
• Fluorides; for external use in liquid form in medicines containing 5500 milligrams or less and more than 1000 milligrams per litre or per kilogram and when sold in packs approved by the Minister or the Director-General for distribution as restricted medicines; for external use in non-liquid form in medicines containing 5500 milligrams or less and more than 1000 milligrams per litre or per kilogram, except in medicines containing 1500 milligrams or less and more than 1000 milligrams per litre or per kilogram and when sold in packs approved by the Minister or the Director-General for distribution as general sale medicines; except when supplied to a dental professional recognised by the Dental Council of New Zealand
• Lansoprazole; in tablets or capsules containing 15 milligrams or less when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine
• Rizatriptan; for oral use in medicines for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms, when in wafers containing 5 milligrams or less per wafer and when sold in a pack containing not more than 2 wafers approved by the Minister or the Director-General for distribution as a restricted medicine
• Staphylococcus aureus vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds
• Streptococcus beta-haemolyticus vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds
• Zolmitriptan; in a prefilled nasal spray device containing not more than 5 milligrams, for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms, when sold in a pack of not more than 2 devices approved by the Minister or the Director-General for distribution as a restricted medicine

Schedule 3

Pharmacy-only Medicines

• Benzocaine; in preparations for topical use, other than eye drops, containing 10% or less of total anaesthetic substances except in dermal preparations containing 2% or less of total anaesthetic substances; in divided preparations containing 200 milligrams or less of total anaesthetic substances per dosage unit except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit
• Brompheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with one or more other therapeutically active ingredients either when in the bed-time dose of a day/night pack containing brompheniramine or when at least one of the other active ingredients is a sympathomimetic decongestant
• Chlorpheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with one or more other therapeutically active ingredients either when in the bed-time dose of a day/night pack containing chlorpheniramine or when at least one of the other active ingredients is a sympathomimetic decongestant
• Codeine; in medicines for oral use, containing not more than 15 milligrams of codeine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of codeine, when combined with 1 or more active ingredients, in such a way that the substance cannot be recovered by readily applicable means or in a yield which would constitute a risk to health, for the treatment of the symptoms of cough and cold and when sold in a pack of not more than 6 days’ supply, approved by the Minister or the Director-General for distribution as a pharmacy-only medicine
• Controlled drugs; that are medicines specified in Part 6 of Schedule 3 of the Misuse of Drugs Act 1975; except codeine as specified elsewhere in this notice
• Dexchlorpheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with one or more other therapeutically active ingredients either when in the bed-time dose of a day/night pack containing dexchlorpheniramine or